Abstract
Leveraging molecular targeted drugs and immune checkpoint inhibitors treat advanced thyroid carcinoma to achieve thyroid carcinoma redifferentiation
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have